O
GH icon

OrbiMed’s Guardant Health GH Stock Holding History

OrbiMed’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$2.02K – 137
2022
Q2 		$2.02K Buy
+50,000
New +$2.48M 0.04% 132

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed's GH Position: Q1 2026 in Review

OrbiMed opened a new position in Guardant Health (GH) in Q1 2026: 435,200 shares worth $40.2M. The stake represents 0.8% of the portfolio and ranks #38 among its holdings. This is a return to the name: OrbiMed previously reported a position in GH as recently as Q3 2022.

OrbiMed first reported a position in GH in Q4 2018 and has held it in 12 quarters since. The position peaked at $153M in Q3 2021. 482 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • OrbiMed held 435,200 shares of Guardant Health worth $40.2M as of Q1 2026.
  • Guardant Health was a new OrbiMed position in Q1 2026.
  • Guardant Health made up 0.8% of OrbiMed's portfolio in Q1 2026, its #38 holding.
  • OrbiMed first reported a position in Guardant Health in Q4 2018 and has held it in 12 quarters since.
  • OrbiMed's Guardant Health position peaked at $153M in Q3 2021.
  • 482 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.